ABSTRACT
We studied the decay of 189W as produced via the 192Os[n,alpha]189W reaction on a 99.9% isotopically enriched 192Os target. The irradiations were performed at the intense neutron beam facility at Cyclotron Research Center, Université Catholique Louvain-la-Neuve (CRC-UCL) (Belgium), where fast neutrons [En approximately 20 MeV, phi(n) = (4.8 +/- 0.3)10(11) ns(-1) cm(-2)] were generated by stopping 50 MeV deuterons on a thick Be target. The half-life of 189W was determined to be 9.3 +/- 0.3min, compared to 10.8 +/- 0.2min obtained from the 188W[n,gamma]189W reaction. The energies of the two predominant gamma-rays of 189W, 260.4 +/- 1.3 and 421.7 +/- 1.4 keV were in good agreement with that from the [n,gamma] reaction, however, the relative intensities of the two gamma-rays were not consistent. From the [n,gamma] reaction, the relative intensities of the 260 and 421 keV gamma-rays were 97 to 100, whereas from the [n,alpha] reaction the relative intensities were 100 to 77, respectively. Assuming a cross-section ratio of 20 +/- 5 for [n,p3n] to [n,alpha] reactions, a cross-section of 0.5 +/- 0.2 mb was suggested for the 192Os[n,alpha]189W reaction, and the absolute intensity of the 260 keV gamma-ray was estimated to be approximately 50%.
ABSTRACT
The feasibility of developing titanium tungstate-based 188W/188Re gel generator using tungsten of natural isotopic abundance irradiated in a moderate flux reactor has been investigated. Influence of temperature, pH and eluent concentration on generator performance was studied. It was found that "post-formed" approach allows to construct gel generators with elution performance and 188Re elution yields very close to those of conventional alumina 188W/188Re generator. Curie-level 185W radionuclidic impurity presents a challenge during the processing of target material and subsequent elution of the generator. In the future use of semi-enriched with 186W target material (50-60% enrichment) would be beneficial in the development of titanium tungstate-based 188W/188Re gel generators.
ABSTRACT
A fundamental task within the framework of a project searching for new radiopharmaceuticals for systemic therapy was the evaluation of the capabilities of the Portuguese Research Reactor (RPI) for the production of several important radionuclides. The feasibility of producing 64Cu, 77As, 153Sm, 165Dy, 166Ho, 170Tm, 177Lu, 186Re, 199Au and 111Ag in useful quantities was evaluated for the present RPI operation schedule (12 h cycles) and for continuous operation. The main evaluation criteria are expressed in terms of specific activity for continuous irradiation and/or 12 h cycle and the use of natural or enriched targets if necessary. Selected samples were irradiated and a comparison between measured activities and values calculated according to the irradiation schedule and using the same software was performed.
Subject(s)
Radioisotopes/isolation & purification , Radioisotopes/therapeutic use , Radiopharmaceuticals/isolation & purification , Radiopharmaceuticals/therapeutic use , Beta Particles/therapeutic use , Copper/radiation effects , Fast Neutrons , Holmium/radiation effects , Humans , Radiochemistry , Rhenium/radiation effects , Samarium/radiation effectsABSTRACT
Temperature influences the stratum corneum adsorption of several topically applied compounds. This study was designed to evaluate the influence of the temperature on the stratum corneum adsorption of 3 UV filters. The UV filters were solubilized in two vehicles, an emulsion gel and petroleum jelly and applied at respectively, 31 and 40 degrees C during 30 min. In vivo stratum corneum UV filter content was measured using the tape stripping method. Similar amounts of UV filter were detected in the stratum corneum when comparing applications at the different temperatures. Application of the UV filters in the emulsion gel resulted in higher stratum corneum UV filter concentrations compared with application in the petroleum jelly. The application temperature did not influence the stratum corneum adsorption of the tested UV filters while the nature of the vehicle significantly influenced the amount of UV filters recovered from the stratum corneum.
Subject(s)
Benzophenones/pharmacology , Cinnamates/pharmacology , Salicylates/pharmacology , Skin Physiological Phenomena , Skin/drug effects , Sunscreening Agents/pharmacology , Ultraviolet Rays , Adult , Emulsions , Gels , Humans , Humidity , Petrolatum , Reproducibility of Results , Skin/radiation effects , TemperatureABSTRACT
BACKGROUND/AIMS: We have recently demonstrated that heme oxygenase-1 is upregulated in splanchnic organs of portal hypertensive rats. In the present study, we assessed whether heme oxygenase enzymatic activity is increased in splanchnic organs of portal hypertensive rats, and the relative contribution of heme oxygenase and nitric oxide synthase to the vascular hyporeactivity in portal hypertension. METHODS: Heme oxygenase activity was measured in splanchnic organs of portal hypertensive and sham-operated rats. The effects of heme oxygenase and nitric oxide synthase inhibition on pressure responses to potassium chloride and methoxamine were assessed in perfused mesenteric vascular beds of portal hypertensive and sham-operated rats. RESULTS: Heme oxygenase activity was increased in the mesentery, intestine, liver, and spleen of portal hypertensive rats. The hyporeactivity to potassium chloride in portal hypertensive rats was overcome after simultaneous inhibition of both heme oxygenase and nitric oxide synthase, but only partially attenuated after nitric oxide synthase inhibition alone. The hyporeactivity to methoxamine was completely reversed after nitric oxide synthase blockade. CONCLUSIONS: These results demonstrate that heme oxygenase activity is increased in splanchnic organs of portal hypertensive rats. They also suggest that heme oxygenase contributes to the hyporeactivity to potassium chloride, but not to methoxamine, in portal hypertensive rats.
Subject(s)
Heme Oxygenase (Decyclizing)/metabolism , Hypertension, Portal/enzymology , Hypertension, Portal/physiopathology , Splanchnic Circulation/physiology , Animals , Enzyme Inhibitors/pharmacology , Heme Oxygenase (Decyclizing)/antagonists & inhibitors , Male , Metalloporphyrins/pharmacology , Methoxamine/pharmacology , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/physiology , Potassium Chloride/pharmacology , Rats , Rats, Sprague-Dawley , Splanchnic Circulation/drug effects , Vasoconstriction/drug effects , Vasoconstriction/physiologyABSTRACT
BACKGROUND/AIMS: The skin irritation potential of a body cleansing product is often compared under exaggerated test conditions, although the product is intended to be used at home with repetitive and brief contact with the skin. The aim of this study was to determine how much patch testing is predictive of the clinical, sub-clinical and subjective cutaneous effects of products used at home by consumers for their normal hygienic cleansing. METHODS: A double-blind comparative study of the normal use of an alkaline soap bar and a syndet at home during 10 consecutive weeks was performed on two identical groups of 25 healthy female subjects. The eventual skin changes observed at different anatomical skin sites were evaluated by clinical visual examination and by bioengineering measurements before the start of the study and then every 2 weeks. The objective measurements were compared with the subject's perceptions of dryness, tightness and product irritancy during the testing. RESULTS: The bioengineering measurements did not show any significant changes on all the anatomical skin sites, except for a small increase in skin pH with the classical soap bar. However, a trend appeared, showing that the alkaline soap bar is perceived by the subjects themselves as more of an irritant than the syndet bar. In the soap chamber test, the bar soap showed a significantly higher irritancy than the syndet bar. CONCLUSION: This study showed that cutaneous irritation induced by cleansing products in patch testing is not necessarily predictive of the irritation likely to occur in normal use conditions. Finally, a clear relationship could be demonstrated between the results of the soap chamber test and the consumer perception of both cleansing bars.
Subject(s)
Irritants , Patch Tests , Skin/drug effects , Soaps/adverse effects , Adult , Biomedical Engineering , Female , Humans , MaleABSTRACT
The increasing demand for radiolabeled metaiodobenzylguanidine (mIBG) prompted the need to obtain the radiopharmaceutical by a reliable, routine and simple synthetic method for batch production. The production of mIBG labeled with either 123I or 124I has been optimized by modifying literature methods that involve solid-state exchange reaction on "cold" mIBG facilitated by ammonium sulfate. The radiochemical yield and purity of radioiodinated mIBG generally exceeded 80 and 98%, respectively, with specific activity of > 50 mCi/mg.
Subject(s)
3-Iodobenzylguanidine/chemical synthesis , Iodine Radioisotopes , Radiopharmaceuticals/chemical synthesis , Ammonium Sulfate , Indicators and ReagentsABSTRACT
Heme oxygenase-1, the major inducible isoform of heme oxygenase (HO), can be induced by heme and numerous other physical and chemical factors, many of which cause cellular 'stress'. This has led to the realization that HO-1 is a major highly conserved stress or heat shock protein. Recent work has implicated activation of mitogen-activated protein kinases and other kinases in the mechanism of induction of HO-1, and suggested that signal transduction pathways through tyrosine kinases are involved in induction of HO-1 gene expression by stress inducers. We hypothesized that phenylarsine oxide (PAO), an inhibitor of protein tyrosine phosphatases (PTPs), might up-regulate the HO-1 gene. Here, we show that a remarkably brief (1-15 min) exposure of normal hepatocytes to low concentrations (0.5-3 microM) of PAO produces a marked increase in mRNA and protein of HO-1. This increase is comparable to the level obtained by addition of heme (20 microM), and occurs without producing changes in cellular glutathione levels or stabilization of HO-1 message. Preincubation of cells with inhibitors of protein synthesis decreased the ability of PAO to increase levels of HO-1 mRNA, suggesting that the inductive effect requires de novo protein synthesis. Addition of thiol donors abrogated the PAO-mediated induction of HO-1 in a dose dependent fashion. Addition of genistein, a tyrosine kinase inhibitor, blunted the induction produced by both PAO and heme. After brief incubations with PAO or heme, cell extracts showed comparable increases in levels of protein tyrosine phosphorylation in general, and specifically in ZAP70 kinase. Our results are consistent with the proposition that induction of HO-1 by PAO involves inhibition of specific PTP(s), and that the mechanisms of induction of HO-1 by PAO and by heme may share some common pathways.
Subject(s)
Arsenicals/metabolism , Heme Oxygenase (Decyclizing)/metabolism , Liver/cytology , Actins/metabolism , Animals , Blotting, Western , Cells, Cultured , Chick Embryo , Dactinomycin/pharmacology , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Genistein/pharmacology , Glutathione/metabolism , Heme Oxygenase-1 , Hepatocytes/metabolism , L-Lactate Dehydrogenase/metabolism , Phosphorylation , Protein Isoforms , Protein-Tyrosine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/metabolism , RNA, Messenger/metabolism , Signal Transduction , Stress, Physiological , Sulfhydryl Compounds/chemistry , Time Factors , Up-Regulation , ZAP-70 Protein-Tyrosine KinaseABSTRACT
Induction of expression of heme oxygenase-1 (HO-1) has been studied in primary cultures of chick embryo liver cells and in the LMH line of avian hepatoma cells. Cells were transiently transfected with selected constructs containing portions of the 5'-untranslated (promoter) region of the HO-1 gene linked to luciferase as reporter gene. LMH cells that had been stably transfected with selected wild type or mutant constructs were also studied. Metalloporphyrins, especially Fe protoporphyrin (heme) and Co protoporphyrin strongly induced luciferase expression in both types of transfected cells. Low concentrations of Zn mesoporphyrin, an inhibitor of HO activity, exerted a synergistic effect on heme-, but not Co protoporphyrin-dependent induction. The antioxidant and &bond;SH donor N-acetyl cysteine had little effect on the metalloporphyrin-dependent inductions of HO-1, in contrast to its marked inhibitory effect on the sodium arsenite-dependent induction of the HO-1 gene. Deletional analysis showed that the key element(s) required for the metalloporphyrin-dependent induction of HO-1 is located between -3.6 and -5.6 kb upstream of the transcription starting point. Data from electrophoretic mobility shift and site-directed mutagenesis experiments excluded a role for consensus AP-1 binding elements at -1576, -3647, or -4578 in the inductions produced by heme or Co protoporphyrin.
Subject(s)
Heme Oxygenase (Decyclizing)/genetics , Metalloporphyrins/pharmacology , Animals , Base Sequence , Cell Line , Cells, Cultured , Chick Embryo , DNA Primers/genetics , Enhancer Elements, Genetic , Gene Expression/drug effects , Genes, Reporter , Heme/pharmacology , Heme Oxygenase-1 , Luciferases/genetics , Mutagenesis, Site-Directed , Promoter Regions, Genetic , Protoporphyrins/pharmacology , TransfectionABSTRACT
Previously, chick heme oxygenase-1 (cHO-1) gene was cloned by us and two regions important for induction by sodium arsenite were identified. These two regions were found to contain consensus sequences of an AP-1 (-1580 to -1573) and a MRE/cMyc complex (-52 to -41). In the current study, the roles of these two elements in mediating the sodium arsenite or cobalt chloride dependent induction of cHO-1 were investigated further. DNA binding studies and site-directed mutagenesis studies indicated that both the AP-1 and MRE/cMyc elements are important for the sodium arsenite induction, while cobalt chloride induction involves only the AP-1 element. Electrophoretic mobility shift assays showed that nuclear protein binding to the AP-1 element was increased by both sodium arsenite or cobalt chloride treatment, whereas the binding of proteins to the MRE/cMyc element showed a high basal expression in untreated cells and the binding activity was only slightly increased by sodium arsenite treatment. Site-directed mutagenesis studies showed that, to completely abolish sodium arsenite induction, both the AP-1 and MRE/cMyc elements must be mutated; mutation of either element alone resulted in only a partial effect. In contrast, a single mutation at AP-1 element was sufficient to reduce the cobalt chloride induction almost completely. The MRE/cMyc complex plays a major role in the basal level expression, and shares some similarities to the upstream stimulatory factor element (USF) identified in the promoter regions of mammalian HO-1 genes and other stress regulated genes. Because sodium arsenite is known to cause oxidative stress and because activation of AP-1 proteins has been shown to be a key step in the oxidative stress response pathway, we also explored the possibility that the induction of the cHO-1 gene by sodium arsenite is mediated through oxidative stress pathway(s) by activation of AP-1 proteins. We found that pretreatment with antioxidants (N-acetyl cysteine or quercetin) reduced the induction of the endogenous cHO-1 message or cHO-1 reporter construct activities induced by sodium arsenite or cobalt chloride. These antioxidants also reduced the protein binding activities to the AP-1 element in the electrophoretic mobility shift assays. In summary, induction of the cHO-1 gene by sodium arsenite or cobalt chloride is mediated by activation of the AP-1 element located at -1,573 to -1,580 of the 5'UTR.
Subject(s)
Heme Oxygenase (Decyclizing)/genetics , Liver/enzymology , Promoter Regions, Genetic , Regulatory Sequences, Nucleic Acid , Animals , Arsenites/pharmacology , Base Sequence , Binding Sites , Cells, Cultured , Chick Embryo , Chickens , Chloramphenicol O-Acetyltransferase/genetics , Cobalt/pharmacology , Consensus Sequence , Enzyme Induction/drug effects , Gene Expression Regulation, Enzymologic/drug effects , Heme Oxygenase (Decyclizing)/biosynthesis , Heme Oxygenase-1 , Liver/cytology , Mammals , Mutagenesis, Site-Directed , Recombinant Fusion Proteins/biosynthesis , Sodium Compounds/pharmacology , Transfection , beta-Galactosidase/geneticsABSTRACT
The dramatic expansion of clinical gene therapy trials requires the development of noninvasive clinical monitoring procedures, which provide information about expression levels, expression kinetics, and spatial distribution of transduced therapeutic genes. With the development of such procedures, invasive sampling of tissue probes from patients potentially could be reduced significantly. In this study, an experimental platform for the rational design and in vitro testing of suitable receptor-ligand couples as components of future transduction tag systems for noninvasive gene therapy monitoring applications was developed. Initially, the feasibility of the delta LNGFR/nerve growth factor (NGF) transduction tag system was investigated; this system employs a mutated version of the low-affinity nerve growth factor receptor (p75mut or delta LNGFR) lacking the entire cytoplasmic domain. Specific binding of 125I-radiolabeled NGF was demonstrated for two stable delta LNGFR-transduced cell lines, but not for delta LNGFR-negative parental control cell lines. An additional binding analysis performed in a MicroImager directly confirmed binding of radiolabeled ligands (125I-NGF, 125I-anti-p75 monoclonal antibody) to the p75mut expressed on intact target cells, but not on control cells. Subsequent binding studies employing NGF radiolabeled with the positron-emitting isotope 124I demonstrated a specific binding for LNGFR+ PC12 cells. Consequently, the first in vitro proof of a transduction tag approach based on the specificity of the 124I-NGF/LNGFR interaction was provided, which opens up the possibility for future noninvasive positron emission tomography monitoring in clinical gene therapy trials.
Subject(s)
Genetic Therapy/methods , Nerve Growth Factor/genetics , Receptor, Nerve Growth Factor/genetics , Retroviridae/genetics , Transduction, Genetic , 3T3 Cells , Animals , Antibodies, Monoclonal/metabolism , Binding Sites, Antibody , Cell Line , Gene Expression Regulation, Neoplastic , Genetic Markers , Iodine Radioisotopes/metabolism , Mice , Nerve Growth Factor/biosynthesis , PC12 Cells , Rats , Receptor, Nerve Growth Factor/biosynthesis , Receptor, Nerve Growth Factor/immunology , Sequence Deletion/genetics , Tomography, Emission-Computed/methodsABSTRACT
BACKGROUND/AIMS: Two types of skin reflectance instruments are available nowadays for the determination of skin color: a tristumulus colorimeter (Chromameter from Minolta) using the CIE L*a*b* color system and the narrow-band simple reflectance meters (DermaSpectrometer from Cortex and Mexameter from Courage-Khazaka) using the erythema/melanin indices. The purpose of this study was to compare the capabilities of the three instruments (sensitivity, repeatability and correlation) in vitro and in vivo. METHODS: Comparative color measurements were carried out first in vitro on standardized color charts and subsequently in vivo on different skin areas in human volunteers. Skin color changes induced by various physico-chemical treatments were also quantitatively evaluated with the three instruments. RESULTS: The in vitro and in vivo repeatabilty as well as the sensitivity of the three instruments are rather good. Erythema and skin blanching could be readily quantified by the increase of the a* parameter and of the erythema indices of the simple reflectance meters. Natural UV tanning and artificial chemical tanning could be measured by the decrease of L* and increase of b* and of the melanin indices. CONCLUSION: The Chromameter and the two narrow-band reflectance instruments were able to characterize skin color and to quantify small skin color changes. Moderate to high significant linear correlations could be established between the CIE L*a*b* color parameters and the erythema/melanin indices.
ABSTRACT
Iron, either in the form of heme or non-heme compounds, is essential to life, but it can also pose serious health risks. The liver is a principal target for iron toxicity because it is chiefly responsible for taking up and storing excessive amounts of iron. The major hepatic toxicities of iron overload include damage to multiple cell types (hepatocytes, Kupffer cells, hepatic stellate cells) and to multiple subcellular organelles (mitochondria, lysosomes, and smooth endoplasmic reticulum). Heavy iron overload, as occurs in primary (hereditary) or secondary forms of hemochromatosis, may cause cirrhosis, liver failure, and hepatocellular carcinoma. In addition, iron has been shown to be a contributory factor in the development or progression of alcoholic liver disease, nonalcoholic liver steatohepatitis, chronic viral hepatitis, prophyria cutanea tarda, and, perhaps, in alpha 1-antitrypsin deficiency and end-stage liver disease, regardless of cause.
Subject(s)
Iron Overload/complications , Liver Diseases/etiology , Fat Necrosis , Hepatitis, Alcoholic/complications , Humans , Iron/adverse effects , Iron/metabolism , Iron Deficiencies , Liver Diseases/diagnosis , Liver Diseases/physiopathology , Porphyria Cutanea Tarda/pathology , Risk Factors , alpha 1-Antitrypsin Deficiency/pathologyABSTRACT
Heme oxygenase catalyzes the first and rate-controlling step of heme catabolism. Induction of heme oxygenase-1 can be caused by numerous factors, including heme, other metalloporphyrins, transition metal ions, heat shock, ultraviolet light, phorbol esters, sodium arsenite, and phenylarsine oxide (PAO). Induction of this enzyme may protect cells from oxidative damage. Using heme oxygenase-1 promoter/reporter gene constructs, we have previously reported that the sodium arsenite-mediated induction of heme oxygenase-1 in chick embryo liver cells and chicken hepatoma (LMH) cells involves an AP-1 element. We have now investigated whether the PAO-mediated induction of heme oxygenase-1 also involves an AP-1 element. Primary cultures of chick embryo liver cells were transiently transfected with heme oxygenase-1 promoter/reporter gene constructs, treated with PAO, and reporter gene activities were measured. We found that the PAO-mediated increase in reporter gene activity was dose- and time-dependent. This activity was decreased by prior treatment with N-acetylcysteine. Studies with mutated constructs showed that both an AP-1 element and a metal responsive element are involved in the PAO-mediated induction of the heme oxygenase-1 reporter construct. Electrophoretic mobility shift assays showed that nuclear proteins from PAO-treated cells had increased binding to an AP-1 probe, and that this increase was abrogated by N-acetylcysteine. These findings support the hypothesis that the PAO-mediated induction of heme oxygenase-1 is caused by activation of AP-1 and MRE/cMyc elements and may involve nuclear proteins whose states of phosphorylation determine binding to regulatory elements, and thus the level of expression of heme oxygenase-1.
Subject(s)
Arsenicals/pharmacology , Gene Expression Regulation, Enzymologic/drug effects , Genes, Reporter/genetics , Heme Oxygenase (Decyclizing)/genetics , Liver/drug effects , Acetylcysteine/pharmacology , Animals , Arsenicals/antagonists & inhibitors , Binding, Competitive , Cells, Cultured , Chick Embryo , DNA/genetics , DNA/metabolism , Dose-Response Relationship, Drug , Heme Oxygenase-1 , Liver/cytology , Liver/metabolism , Mutation/genetics , Nuclear Proteins/metabolism , Promoter Regions, Genetic/genetics , Protein Tyrosine Phosphatases/antagonists & inhibitors , Proto-Oncogene Proteins c-myc/physiology , Response Elements/genetics , Transcription Factor AP-1/metabolism , TransfectionABSTRACT
Patients with any of the acute porphyrias may suffer from acute attacks. If these patients are treated with certain drugs, such as barbiturates, the likelihood of developing an attack is increased. Patients treated with antidepressants or benzodiazepine-type anxiolytics also could be placed at increased risk of developing porphyric attacks because little is known about the potential for some of these drugs to induce attacks. Primary cultures of chick embryo liver cells were used to study the effects of selected antidepressants and anxiolytics on porphyrin accumulation. Cells were treated with desferrioxamine (to partially block heme synthesis, simulating conditions encountered in porphyric patients) and increasing concentrations (3.16-1000 microM) of the evaluated drugs. Twenty hours later, porphyrin accumulation was measured. The drugs included four antidepressants and five benzodiazepine-type anxiolytics. The antidepressants bupropion and nefazodone significantly increased porphyrin accumulation when given with desferrioxamine, whereas neither fluoxetine nor paroxetine increased porphyrin accumulation. The benzodiazepine-type anxiolytic agents oxazepam, lorazepam, diazepam, triazolam, and midazolam all significantly increased porphyrin accumulation when given with desferrioxamine. Dose-response studies showed that diazepam, midazolam, and triazolam produced significant increases even at the lowest concentration tested (3.16 microM), whereas lorazepam and oxazepam required higher concentrations (>/=10 microM). These studies suggest that patients with acute porphyrias may be at greater risk for developing porphyric attacks when treated with bupropion or nefazodone compared with fluoxetine or paroxetine, and that the evaluated benzodiazepine derivatives should be administered with caution. Among the latter, low doses of lorazepam and oxazepam may be safer than those of diazepam, midazolam, and triazolam.
Subject(s)
Anti-Anxiety Agents/pharmacology , Antidepressive Agents/pharmacology , Liver/metabolism , Porphyrins/biosynthesis , Animals , Benzodiazepines , Cells, Cultured , Chick Embryo , Dose-Response Relationship, Drug , Liver/cytology , Porphyrias/chemically induced , Porphyrias/pathology , Proteins/metabolismABSTRACT
BACKGROUND/AIMS: Non-alcoholic steatohepatitis (NASH) is increasingly recognized, and its pathogenesis is believed to involve increased oxidative stress. Elevated levels of serum ferritin and positive liver iron stains are often observed in patients with NASH, and the pathogenesis of liver injury due to iron is also thought to involve oxidative stress. The aim of this study was to determine whether there is an association of NASH and mutations in the HFE gene associated with hereditary hemochromatosis (HHC). METHODS: Clinical, laboratory, and histopathological data on all 57 subjects with a final diagnosis of NASH seen between August 1990 and August 1997 at our Liver Center were analyzed. Thirty-six Caucasian subjects (23 men) with NASH underwent mutational analyses of HFE gene mutations performed. The prevalence of HFE gene mutations was compared to that in 348 Caucasian normal controls. Data were analyzed by both parameteric and non-parametric methods with similar results. RESULTS: One subject (2.8%) with NASH was homozygous for the C282Y mutation and six (16.7%) were heterozygous, compared with 0%, and 11.2%, respectively, of controls. Two (5.6%) subjects with NASH were homozygous for the H63D mutation and 16 (44.4%) were heterozygous, whereas 2.9% and 26.4%, respectively, of controls had these genotypes. The prevalence of heterozygosity (61.1%) for either mutation was significantly higher in subjects with NASH than in controls (38%) (p = 0.008), and the prevalence of homozygosity or heterozygosity combined in NASH subjects (69.4%) was significantly higher than for controls (40.5%, p = 0.001). Sex (63-67% male) and age at diagnosis of NASH did not differ between those with or without HFE mutations, but men with NASH were significantly more likely than women to have the H63D mutation (15/23 vs. 3/13, p<0.05) Levels of serum ferritin, iron, transferrin saturation levels, and the degree of hepatic iron staining were significantly higher (p<0.05) in subjects with NASH who carried an HFE mutation than in those without. Differences in hepatic iron concentrations or hepatic iron indices between NASH subjects with and without HFE mutations were not significant. Those with C282Y mutations had significantly more hepatic fibrosis than those without (p<0.05). Those with HFE mutations had significantly higher levels of serum ALT (90+/-11 [mean +/- SE]) than those without (55+/-6; p = 0.02). CONCLUSION: The prevalences of the HFE gene mutations associated with hereditary hemochromatosis are increased among North American subjects with NASH.
Subject(s)
Chemical and Drug Induced Liver Injury/etiology , Fatty Liver/chemically induced , Genes, MHC Class I , HLA Antigens/genetics , Hemochromatosis/genetics , Histocompatibility Antigens Class I/genetics , Iron/adverse effects , Membrane Proteins , Adult , Female , Hemochromatosis Protein , Humans , Male , Middle Aged , Mutation , Prevalence , Retrospective StudiesABSTRACT
When patients with acute porphyrias are treated with antihypertensives and analgesics, they could be placed at increased risk of developing porphyric attacks, since little is known about the potential for many of these drugs to induce these attacks. We used primary chick embryo liver cells, which maintain intact heme synthesis and regulation, to study the effects of antihypertensives and analgesics on porphyrin accumulation. Cells were treated with desferrioxamine to block heme synthesis partially, simulating conditions encountered in porphyric patients. Typically, cells were treated for 20 hr with the test drugs (3.16 to 1000 microM), along with desferrioxamine. Porphyrins were measured spectrofluorometrically, as uro-, copro,- and protoporphyrin. The evaluated drugs included six antihypertensives (two calcium channel blockers, an angiotensin receptor antagonist, and three inhibitors of angiotensin converting enzyme) and eight analgesics. Of the calcium channel blockers tested, nifedipine greatly increased porphyrin accumulation, whereas diltiazem caused only a slight increase. Losartan (an angiotensin receptor antagonist), captopril, or lisinopril (two angiotensin converting enzyme inhibitors) produced only small increases in porphyrin accumulation. In contrast, enalapril (another angiotensin converting enzyme inhibitor) substantially increased porphyrin accumulation when given in high concentrations. Among the analgesics tested, fentanyl and tramadol produced the highest porphyrin accumulations. Nalbuphine, hydrocodone, oxycodone, and dezocine were moderately or weakly porphyrogenic, whereas buprenorphine and morphine did not increase porphyrin accumulation. These studies suggest that patients with acute porphyrias may be at greater risk for developing porphyric attacks when treated with nifedipine (compared with diltiazem), enalapril (compared with captopril or lisinopril), and tramadol (compared with the other analgesics).
Subject(s)
Analgesics/pharmacology , Antihypertensive Agents/pharmacology , Porphyrias, Hepatic/chemically induced , Porphyrins/metabolism , Analgesics/adverse effects , Animals , Antihypertensive Agents/adverse effects , Cells, Cultured , Chick Embryo , Liver/cytology , Liver/drug effects , Porphyrias, Hepatic/metabolismABSTRACT
To further the understanding of oxidative effects on inflammation injury to muscle fiber structure, fluorescent imaging analysis of human striated muscle tissues from a variety of inflammatory or postinflammatory etiologies was undertaken in a search for accumulated coproporphyrin, a red autofluorescent byproduct of heme biosynthesis that would theoretically be formed under oxidative insult. Using a differential excitation method of in situ analysis, porphyrin autofluorescence was detected in intact fibers within the context of the yellow autofluorescent subsarcolemmal lipofuscin granules. Relative measurements of porphyrin concentration in the granules from different patients indicated that the acute/subacute inflammatory specimens grouped significantly higher than the more chronic inflammatory and nonpathological specimens. Myoglobin was also found to be associated with the granules. Myoglobin heme iron could potentially serve as a Fenton reagent for the intracellular generation of hydroxyl radicals, which are responsible for the oxidation of the porphyrinogens. High-performance liquid chromatography analysis of extracted dense particles revealed coproporphyrin as the sole porphyrin present. The observation of coproporphyrin within lipofuscin granules, previously unreported, suggests that lipofuscin accumulation in striated muscle may begin under conditions of acute oxidative stress, as marked by the oxidation of extramitochondrial porphyrinogens that are immediately incorporated into the granules.
Subject(s)
Coproporphyrins/metabolism , Lipofuscin/metabolism , Muscle, Skeletal/metabolism , Myositis/metabolism , Animals , Cytoplasmic Granules/metabolism , Fluorescence , Humans , Image Processing, Computer-Assisted , Isoproterenol/toxicity , Male , Muscle, Skeletal/pathology , Myocardial Infarction/chemically induced , Myocardial Infarction/metabolism , Myocardial Infarction/pathology , Myocardium/metabolism , Myocardium/pathology , Myoglobin/analysis , Myositis/pathology , Rats , Rats, Wistar , Sarcolemma/metabolismABSTRACT
In some, but not all countries, porphyria cutanea tarda (PCT) has been associated with chronic infection with the hepatitis C virus (HCV). Recently, PCT has also been associated with mutations in the HFE gene that are associated with HLA-linked hereditary hemochromatosis. Until now, few studies of these associations have been reported from North America. The aims of this study were: 1) to assess the prevalence of HCV infection and HFE mutations in North American patients with PCT; 2) to compare demographic and laboratory features between those who are HCV-positive and HCV-negative; and 3) to study urinary porphyrin excretions in American HCV-positive patients without clinically manifest PCT. Clinical and laboratory data, including tests for HCV and urinary porphyrins, were collected from 70 unselected patients with typical PCT. Urinary porphyrins were also measured in 110 non-PCT patients with chronic hepatitis C. Mutational analyses of the HFE gene were performed in 26 PCT patients. Thirty-nine of 70 (56%) of the PCT patients had evidence of HCV infection. Thirty-two of 39 PCT patients with HCV were men, all of whom used alcohol. In contrast, 22 of 31 PCT patients without HCV infection were women, 12 of whom had taken estrogens. The HCV-positive group was more likely to have used illicit intravenous drugs (45% vs. 0%; P = 0.01), to have had several (>4) sex partners (48% vs. 13%; P = 0.005), and less likely to have no known risk factors for HCV infection (33% vs. 78%; P = 0.004). Total urinary porphyrin excretion was the same in the two groups, but those with HCV infection had a significantly lower percentage of uroporphyrin and higher percentages of hepta-and hexa-carboxy porphyrins in urine. Sixteen of 110 (15%) HCV-positive subjects without PCT had increased urinary porphyrins, but, unlike PCT, these were mainly coproporphyrin. Forty-two percent of PCT patients carried the C282Y mutation of HFE (15% homozygous), and another 31% carried the H63D mutation (8% homozygous). Thus, 73% of PCT patients had one of these mutations. The prevalence of HCV infection (56%) and mutations in the HFE gene (73%) are high among North American patients with PCT. Alcohol and estrogen use are important additional risk factors. All PCT patients should be tested for HCV infection and for HFE gene mutations. Although HCV infection is a trigger for PCT, preclinical PCT is rare in chronic HCV hepatitis C in the United States.
Subject(s)
HLA Antigens/genetics , Hepacivirus/isolation & purification , Hepatitis C/genetics , Histocompatibility Antigens Class I/genetics , Membrane Proteins , Mutation , Porphyria Cutanea Tarda/genetics , Adult , Aged , Female , Hemochromatosis Protein , Hepatitis C/epidemiology , Hepatitis C/immunology , Humans , Male , Middle Aged , North America/epidemiology , Porphyria Cutanea Tarda/epidemiology , Porphyria Cutanea Tarda/immunology , Porphyria Cutanea Tarda/virologyABSTRACT
The aim of this study was to assess the utility of a radioimmunoconjugate containing a lead radionuclide for therapy and scintigraphy applications. The radioimmunoconjugate evaluated consisted of a bifunctional DOTA ligand and monoclonal antibody (MAb) B72.3 using athymic mice bearing LS-174T tumors, human colon carcinoma xenografts. In the studies reported here, the lead-203-DOTA complex itself was first demonstrated to have in vivo stability. MAb B72.3 was then conjugated with the DOTA ligand and labeled with 203Pb, and the immunoreactivity of B72.3 was maintained. The localization of the radioimmunoconjugate to tumor tissue and other select organs paralleled that of DOTA-125I-B72.3, suggesting a similar metabolic pattern of the two radioimmunoconjugates. Thus, the DOTA-metal complex does not alter the behavior of the radioimmunoconjugate. Tumor localization of the 203Pb-DOTA-B72.3 conjugate was demonstrated with biodistribution studies as well as immunoscintigraphy studies. Such data highlight the stability of a lead radionuclide in the DOTA ligand. The suitability of this chelation chemistry for labeling radioimmunoconjugates with a lead radionuclide now makes its application in nuclear medicine a feasible proposition.